ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ABUS Arbutus Biopharma Corporation

3.33
0.01 (0.30%)
01 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Arbutus Biopharma Corporation NASDAQ:ABUS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.01 0.30% 3.33 3.29 3.36 3.385 3.31 3.32 831,299 01:00:00

Arbutus to Participate in Two Upcoming Investor Conferences

07/05/2024 12:30pm

GlobeNewswire Inc.


Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart


From May 2024 to Jun 2024

Click Here for more Arbutus Biopharma Charts.

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in New York:

  • The Citizens JMP Life Sciences Conference: Fireside Chat on May 14, 2024 at 9:30 am ET
  • H.C. Wainwright 2nd Annual BioConnect Investor Conference: Fireside Chat on May 20, 2024 at 3:30 pm ET

To access the live webcast of the fireside chats please visit: https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.

About Arbutus

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in three Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. For more information, visit www.arbutusbio.com.

Contact Information

Investors and Media

Lisa M. CaperelliVice President, Investor RelationsPhone: 215-206-1822Email: lcaperelli@arbutusbio.com

1 Year Arbutus Biopharma Chart

1 Year Arbutus Biopharma Chart

1 Month Arbutus Biopharma Chart

1 Month Arbutus Biopharma Chart